

Substitute for form 144B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)			Complete if Known		
			Application Number	<del>To Be Assigned</del> 10/820216	
			Filing Date	FDA April 7, 2004	
			First Named Inventor	Baudy et al.	
			Group Art Unit	1624	
Examiner Name	COLEMAN				
Attorney Docket Number	AM101277				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number (If known)	Kind Code (If Known)			class	subclass
BC	1.	5,168,103		Kinney et al.	12-01-1992	514	221
BC	2.	5,990,307		Asselin et al.	11-23-1999	540	542
BC	3.	6,011,168		Asselin et al.	01-04-2000	558	172
BC	4.	5,240,946		Kinney et al.	08-31-1993	514	364
BC	5.	5,624,898		William H. Frey, II	04-29-1997	514	12
BC	6.	6,451,848	B1	Behl et al.	09-17-2002	514	468
BC	7.	5,124,319		Baudy et al.	06-23-1992	514	80
BC	8.	2003-0114444	A1	Brandt et al.	06-19-2003	514	221

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
BC	9.	EP	0 496 561	A2	American Home Products Corp.	07-29-1992		<input type="checkbox"/>
BC	10.	WO	98/15542	A1	H. Lundbeck A/S	04-16-1998		
BC	11.	EP	0 994 107	A1	H. Lundbeck A/S	04-19-2000		
BC	12.	EP	0 778 023	A1	American Home Products Corp.	06-11-1997		
BC	13.	WO	99/06417	A1	American Home Products Corp.	02-11-1999		
BC	14.	WO	99/64041	A1	Advanced Medicine, Inc.	12-16-1999		
BC	15.	WO	03/031416	A2	Wyeth	04-17-2003		

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
BC	16.	KARLSTEN et al., Drug & Aging, 11(5), 398-412 (1997).		<input type="checkbox"/>
BC	17.	HAO et al., Pain, 66, 279-285 (1996).		
BC	18.	CHAPLAN et al., Pharmacology & Experimental Therapeutics, 280(2), 829-838 (1997).		
BC	19.	SUZUKI et al., Pain, 91, 101-109 (2001).		
BC	20.	BENNETT, Journal of Pain & Symptom Management, 19(1 Suppl.), S2-S6 (2000).		
BC	21.	SANG, Journal of Pain & Symptom Management, 19(1 Suppl.), S21-S25 (2000).		
BC	22.	PAL et al., Burns, 23(5), 404-412 (1997).		
BC	23.	ROGAWSKI et al., Trends in Pharmaceutical Sciences, 14, 325-331 (1993).		
BC	24.	NICHOLSON et al., Behavioural Pharmacology, 9, 231-243 (1998).		
BC	25.	MORI et al., Behavioural Brain Research, 119, 33-40 (2001).		
BC	26.	BARON et al., Psychopharmacology, 118, 42-51 (1995).		
BC	27.	FRANCE et al., Journal of Pharmacology & Experimental Therapeutics, 257(2), 727-734 (1991).		
BC	28.	FRANCE et al., European Journal of Pharmacology, 159, 133-139 (1989).		
BC	29.	OLNEY et al., Science, 254, 1515-1518 (1991).		
BC	30.	FIX et al., Experimental Neurology, 123, 204-215 (1998).		
BC	31.	BRADFORD et al., Stroke & Cerebral Circulation, Abstract (1998).		
BC	32.	MILLAN et al., Neuroscience Letters, 178, 139-143 (1994).		
BC	33.	KINNEY et al., J. Med. Chem., 41, 236-246 (1998).		
BC	34.	MCROBERTS et al., Gastroenterology, 120(7), 1737-1748 (2001).		
BC	35.	OLIVAR et al., Pain, 79, 67-73 (1999).		
BC	36.	RYGH et al., Pain, 93, 15-21 (2001).		
BC	37.	TANG et al., Nature, 401, 63-69 (1999).		
BC	38.	WEI et al., Nature, 4(2), 164-169 (2001).		
BC	39.	CHAPLAN, S.R., Journal of Neuroscience Methods, 53, 55-63 (1994).		

Examiner Signature	Brenda Coleman	Date Considered	May 25, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 144B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Complete if Known			
		Application Number	To Be Assigned 10/820216		
		Filing Date	TBA April 7, 2004		
		First Named Inventor	Baudy et al.		
		Group Art Unit	1624		
		Examiner Name	COLEMAN		
Sheet	2	of	2	Attorney Docket Number	AM101277

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
BC	40.	BENNETT, Gary et al., Pain, 33, 87-107 (1988).	
BC	41.	HEWITT, David, The Clinical Journal of Pain, 16, S73-S79 (2000).	
BC	42.	WOOLF, et al., Pain, 44, 293-299 (1991).	
BC	43.	OLNEY, et al., Science, 244, 1360-1362 (1989).	
BC	44.	ABRAHAMS et al., Emerging Drugs, 5(4), 385-413 (2000).	
BC	45.	HERRLING, P.L., Academic Press, Chapter 1, 1-6 (1997).	
BC	46.	BAUDY et al., J. Med. Chem. 36, 331-342 (1993).	<input type="checkbox"/>
BC	47.	KRISTENSEN, et al., Database Biosis, Biosciences Information Service, Abstract XP002228851, 1992	
BC	48.	BAUDY et al., J. Med. Chem. 44, 1516-1529 (2001).	
BC	49.	CHILDERS et al., Drugs of the Future, 27(7), 633-638 (2002).	
BC	50.	KRISTENSEN, et al., Pain, 51, 249-253 (1992).	
BC	51.	ABOU-GHARBIA, Abstract Paper, Am. Chem. Soc., 221 <sup>st</sup> MEDI 202 (2001).	
BC	52.	B.M. SWAHN et al., Bioorganic & Medicinal Chemistry Letters, 6(14), 1635-1640 (1996).	<input type="checkbox"/>
BC	53.	S.H. WILEN et al., Tetrahedron, 33, 2725-2736 (1977).	
BC	54.	C.R. BEHL et al., Advanced Drug Delivery Reviews, 29, 117-133 (1998).	
BC	55.	A. HUSSAIN, Advanced Drug Delivery Reviews, 29, 39-49 (1998).	
BC	56.	T. MOSCONI et al., Pain, 64, 37-57 (1996).	
BC	57.	M. BRANDT et al., The Journal of Pharmacology & Experimental Therapeutics, 296(3), 939-946 (2001).	
BC	58.	H. ZIA et al., Clinical Research & Regulatory Affairs, 10(2), 99-135 (1993).	
BC	59.	G.D. PARR, Pharmacy International, 4, 202-205 (1983).	
BC	60.	G.J. BENNETT et al., Pain, 33, 87-107 (1988).	
BC	61.	S.C. SUTTON et al., Pharmaceutical Research, 10(6), 924-926 (1993).	
BC	62.	S.R. CHAPLAN et al., Journal of Neuroscience Methods, 53, 55-63 (1994).	
BC	63.	F. MENNITI, et al., European Journal of Pharmacology, 331, 117-126 (1997).	
BC	64.	B. CHIZH et al., TRENDS in Pharmacological Sciences, 22(12), 636-642 (2001).	
BC	65.	S. BOYCE et al., Neuropharmacology, 38, 611-623 (1999).	
BC	66.	V. MUTEL et al., Journal of Neurochemistry, 70, 2147-2155 (1998).	

Examiner Signature	Brenda Coleman	Date Considered	May 23, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/820,216
(use as many sheets as necessary)		Filing Date	April 7, 2004
		First Named Inventor	BAUDY et al.
		Group Art Unit	1624
		Examiner Name	COLEMAN
		Attorney Docket Number	AM101277
Sheet	1	of	1




U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	Number (If known) 2005/0004049 Kind Code (If known) 10/820,216	Eric J. Benjamin et al.	Jan. 6, 2005 Not Published	class 514 subclass 80

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	2.	Office	Number	Kind Code (If Known)				<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
BC	3.	ROGERS, Kathryn, Wyeth-Perzinfotel (EAA-090) NMDA Antagonist for the Treatment of Diabetic Neuropathy, 47 pages, presented on June 9, 2004 at the SMI Pain Conference, London, England.	<input type="checkbox"/>

Examiner Signature	Brenda Coleman	Date Considered	May 25, 2006
--------------------	----------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO <div style="text-align: center;">  <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p> </div>				<b>Complete if Known</b>			
				Application Number	10/820,216		
				Filing Date	April 7, 2004		
				First Named Inventor	BAUDY et al.		
				Group Art Unit	1624		
				Examiner Name	COLEMAN		
				Attorney Docket Number	AM101277		
Sheet <u>1</u> of <u>1</u>							

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If Known)	Kind Code (If Known)			
BC	1.	2005/0142192		Benjamin et al.	06-30-2005	class 424 subclass 464
BC	2.	2004/0082543	A1	Pharmacia Corporation	04-29-2004	514 80

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
BC	3.	WO	2004/039371	A2	Pharmacia Corporation	05-13-2004		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
BC	4.	KINNEY W.A., et al., Journal of Medicinal Chemistry, 35(25), 4720-4726 (1992).			<input type="checkbox"/>
BC	5.	HATSE S., et al., Molecular Pharmacology, 50(5), 1231-1242 (1996).			
BC	6.	FARQUHAR D, et al., Journal of Pharmaceutical Sciences, 72(3), 324-325 (1983).			
BC	7.	LOMBAERT S DE, et al., Journal of Medicinal Chemistry, 37(4), 498-511 (1994).			
BC	8.	STARRETT J.E., et al., Journal of Medicinal Chemistry, 37(12), 1857-1864 (1994).			
BC	9.	FARQUHAR D, et al., Journal of Medicinal Chemistry, 37(23), 3902-3909 (1994).			
BC	10.	LEFEBVRE I, et al., Journal of Medicinal Chemistry, 38(20), 3941-3950 (1995).			
BC	11.	OLIYAI R, et al., Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), 1295-1298 (2001).			
BC	12.	YUAN L.C., et al., Pharmaceutical Research, 18(2), 234-237 (2001).			
BC	13.	FRANKOVA D, et al., Nucleosides & Nucleotides, 18(4/5), 955-958 (1999).			
BC	14.	EISENBERG E J, et al., Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), 1091-1098 (2001).			
BC	15.	ROBBINS B L, et al., Antimicrobial Agents and Chemotherapy, 42(3), 612-617 (1998).			
BC	16.	NAESENS L., et al., Antimicrobial Agents and Chemotherapy, 42(7), 1568-1573 (1998).			
BC	17.	MULATO A.S., et al., Antimicrobial Agents and Chemotherapy, 42(7), 1098-1107 (1998). 1620-1628			
BC	18.	KAHN S.R., et al., Tetrahedron Letters, 40(4), 607-610 (1999).			

Examiner Signature	Brenda Coleman	Date Considered	May 30, 2006
-----------------------	----------------	--------------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.